Roche Holding AG (RHHBY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to Roche's first quarter sales webinar 2026. My name is Henrik and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. I'd like to inform you that all participants are in listen-only mode during the call. After the presentation, there will be a question and answer session. You are invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom. In addition to that, you may also raise your virtual hand to address your questions verbally. For participants joining via phone, to raise your hand, use star nine on your phone's dial pad. When you then get selected to ask your questions, please follow the instructions from the phone and press star six to unmute yourself. One last remark, if you'd like to follow the presented slides on your end as well, please feel free to go to wolf.com slash investors to download the presentation. At this time, it's our pleasure to introduce you to Thomas Schoenecker, CEO of Wash Group. Mr. Schoenecker, the stage is yours. Thank you very much and good morning and good afternoon to everyone. I'm very much excited to share our Q1 2026 results with you. Overall, very strong performance in sales in the first quarter and including there are some clinical and regulatory milestones that we have achieved. Now let's start on the performance side. Q1 was strong with group sales at plus 6%, driven by pharma with plus 7%. Diagnostics grew plus 3% despite headwinds from the China healthcare pricing reforms, which we are still experiencing in the first half year. Excluding China, diagnostics was at plus 5%. In addition, a weaker and earlier flu season impacted the sales of Sufluza and on the diagnostic side, the respiratory sales in point of car...